Similar articles for PMID: 26742710

Year	Number of Results
1948	1
1950	1
1983	1
1988	1
1990	2
1991	1
1992	1
2002	1
2003	1
2004	1
2005	3
2007	2
2008	6
2009	2
2010	14
2011	16
2012	19
2013	18
2014	33
2015	29
2016	36
2017	31
2018	20
2019	23
2020	20
2021	20
2022	19
2023	3
2024	0

1

Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.

Fendler WP, Lechner H, Todica A, Paprottka KJ, Paprottka PM, Jakobs TF, Michl M, Bartenstein P, Lehner S, Haug AR. Fendler WP, et al. J Nucl Med. 2016 Apr;57(4):517-23. doi: 10.2967/jnumed.115.165050. Epub 2016 Jan 7. J Nucl Med. 2016. PMID: 26742710 Free article.

2

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M. Haug AR, et al. J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331219 Free article.

3

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR. Fendler WP, et al. J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31. J Nucl Med. 2013. PMID: 23729697 Free article.

4

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS. Piduru SM, et al. J Vasc Interv Radiol. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19. J Vasc Interv Radiol. 2012. PMID: 22609292 Clinical Trial.

5

Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.

Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM, Lewandowski RJ, Nagle C, Salem R. Wong CY, et al. J Vasc Interv Radiol. 2005 Aug;16(8):1101-6. doi: 10.1097/01.RVI.0000168104.32849.07. J Vasc Interv Radiol. 2005. PMID: 16105922

6

Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.

Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Abuodeh Y, et al. World J Gastroenterol. 2016 Dec 21;22(47):10406-10414. doi: 10.3748/wjg.v22.i47.10406. World J Gastroenterol. 2016. PMID: 28058021 Free PMC article.

7

Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.

Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, Boeck S, Albert NL, Fendler WP. Michl M, et al. J Nucl Med. 2016 Mar;57(3):355-60. doi: 10.2967/jnumed.115.165613. Epub 2015 Nov 25. J Nucl Med. 2016. PMID: 26609176 Free article.

8

Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.

Gunduz S, Ozgur O, Bozcuk H, Coşkun HS, Ozdogan M, Erkilic M, Sindel T, Yldlzs A, Ylmaz S, Boz A, Aydin F, Karayalçin B, Savas B. Gunduz S, et al. Hepatogastroenterology. 2014 Sep;61(134):1529-34. Hepatogastroenterology. 2014. PMID: 25436337

9

Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.

Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S. Padia SA, et al. J Vasc Interv Radiol. 2013 Aug;24(8):1147-53. doi: 10.1016/j.jvir.2013.04.018. Epub 2013 Jun 20. J Vasc Interv Radiol. 2013. PMID: 23792126

10

Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.

Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Saxena A, et al. Ann Surg Oncol. 2014 Apr;21(4):1296-303. doi: 10.1245/s10434-013-3436-1. Epub 2013 Dec 15. Ann Surg Oncol. 2014. PMID: 24337647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

278 results

Results by year